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Abstract The cytotoxic T lymphocyte (CTL) response has
recently been shown to play a role in protection against human
immunodeficiency virus (HIV) and it is therefore thought that a
vaccine against HIV must be able to elicit a CTL response. The
development of a safe, effective adjuvant is very important
because alum, the only adjuvant available for use in humans at
present, can barely induce a response of this type. We
demonstrate here that liposomes that contain an immunodomi-
nant peptide (15 amino acids) of the envelope glycoprotein gp120
of HIV-1 and that are coated with mannopentaose-dipalmitoyl-
phosphatidylethanolamine conjugate induce a major histocom-
patibility complex class I-restricted CD8+ CTL response in mice
with a single subcutaneous immunization, whereas non-coated
liposomes do not. Since no damage to the skin at the injection site
was caused by the liposomes, and since the oligomannose-coated
liposomes consist of innocuous materials ubiquitously distributed
throughout the human body, they may be highly suitable for use
as a safe adjuvant in vaccines inducing a CTL response against
HIV.
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1. Introduction
Cell-mediated immune response such as the cytotoxic T
lymphocyte (CTL) response is deeply involved in protective
immunity against infection by human immunode¢ciency virus
(HIV) [1]. In HIV-1 infection, in addition to the production of
antibodies, CTL responses may be detected that are speci¢c to
epitopes in the envelope glycoprotein, the gag proteins, and
other HIV proteins including reverse transcriptase [2]. Among
people infected with HIV, long-term non-progressors show an
especially strong CTL response against HIV, suggesting that
CTL may be able to control HIV infection and progression to
AIDS [3,4]. Thus, elicitation of CTL response is considered to
be required in a vaccine against HIV [5]. It is well-known that
HIV proteins and their epitope peptides that induce a CTL
response against HIV do not induce such responses unless
they are administered together with an adjuvant. Although
various adjuvants that induce cellular immunity have been
found, they are used only in animals because of their toxicity
to humans. Alum adjuvant, which is made of aluminum hy-
droxide or aluminum phosphate and which is the only adju-
vant available for use in humans at present, cannot induce a
response of this type. Therefore, the development of an adju-
vant that is safe for humans and that can induce a CTL
response is very important.
The surfaces of various infectious agents such as viruses [6],
bacteria [7], fungi [8], and protozoa [9] are coated with carbo-
hydrate moieties rich in mannose residues. Antigen-presenting
cells such as macrophages and dendritic cells have been shown
to express mannose receptors on the cell surface [10^15]. In
the present study, we prepared oligomannose-coated lipo-
somes using a neoglycolipid constructed with mannopentaose
and dipalmitoylphosphatidylethanolamine (which are ubiqui-
tously found in the human body) as a new candidate for a safe
adjuvant and examined whether the liposomes encapsulating
the epitope peptides of the HIV envelope glycoprotein gp120
perform an adjuvant activity to induce an epitope-speci¢c
CTL response.
2. Materials and methods
2.1. Materials
Synthetic peptides 18IIIB (RIQRGPGRAFVTIGK) and 18I10
(RGPGRAFVTI) were obtained from Iwaki Co. (Chiba, Japan). Di-
palmitoylphosphatidylcholine and mannopentaose with a structure of
ManK1-6(ManK1-3)ManK1-6(ManK1-3)Man were purchased from
Funakoshi Co. (Tokyo, Japan). Dipalmitoylphosphatidylethanol-
amine and cholesterol were obtained from Sigma-Aldrich Japan (To-
kyo, Japan). Anti-CD8 (anti-Ly-2.2) monoclonal antibody and rabbit
complement (Low-Tox-M Rabbit Complement) were obtained from
Cederlane Laboratories Ltd. (Ontario, Canada).
The neoglycolipid-containing oligomannose was prepared by con-
jugation of mannopentaose and dipalmitoylphosphatidylethanolamine
using a method described previously [16,17].
2.2. Preparation of oligomannose-coated liposomes
Liposomes (multilamellar vesicles) were prepared as follows: 750 Wl
of a chloroform-methanol (2:1, v/v) solution containing 5 Wmol of
dipalmitoylphosphatidylcholine and 2.5 Wmol of cholesterol was
placed in a conical £ask and rotary evaporated to prepare a lipid
¢lm. 250 Wl of PBS or PBS containing 1.25 mg of synthetic peptide
was added to the dried lipid ¢lm and multilamellar vesicles were then
prepared by intense vortex dispersion. The amount of liposomes thus
obtained was measured as the amount of dipalmitoylphosphatidylcho-
line. Liposomes were coated with oligomannose by incubation with
the neoglycolipid at 12‡C for 3 days. The coating of liposomes with
the neoglycolipid was con¢rmed by their agglutination by concanava-
lin A and by composition analysis of the coated liposomes.
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2.3. Immunization of mice
BALB/c mice were subcutaneously immunized for CTL assay once
on both sides of the dorsal skin near the base of the tail with the
liposomes, which contained 200 Wg of dipalmitoylphosphatidylcholine
and 0 or 3 Wg of peptide, and which were either coated or not coated
with 6 Wg of the neoglycolipid. BALB/c mice given PBS were used as
non-immunized mice. Separately, BALB/c mice were intravenously
immunized once with the same amount of the oligomannose-coated
liposomes containing the peptide.
In order to examine production of antibody against oligomannose,
30 Wg of the neoglycolipid containing the mannopentaose was subcu-
taneously injected to BALB/c mice three times at intervals of 3 weeks.
Mice given PBS were used as non-immunized mice. One week after
the last injection, sera were analyzed for antibody production by
enzyme immunoassay using the neoglycolipid as antigen.
2.4. CTL assay
Four to six weeks after immunization, spleen cells (5U106 cells/ml
of RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml
penicillin, 100 Wg/ml streptomycin, and 50 WM 2-mercaptoethanol)
were re-stimulated in vitro with 0.3 WM peptide 18IIIB. After 6 days
of culture, the cytolytic activity of the re-stimulated cells was
measured using a conventional 4-h assay with target cells (1U104 cells
per well) at the indicated e¡ector:target cell ratios. Syngeneic P815
cells pulsed with or without 1 WM of 10-mer peptide 18I10 were
labeled with Na51CrO4 and used as target cells. The percent speci¢c
51Cr release was calculated as: 100U(experimental release3spontane-
ous release)/(total release3spontaneous release). Total release was de-
termined from the radioactivity in the supernatants of cells that were
lysed by addition of 5% Triton X-100. Results are expressed as %
speci¢c 51Cr release.
3. Results and discussion
The synthetic peptide of the CTL epitope (18IIIB;
RIQRGPGRAFVTIGK) from the envelope glycoprotein
gp120 of HIV-1 [18,19] was incorporated into liposomes,
which were then coated with oligomannose using a neoglyco-
lipid constructed with ManK1-6(ManK1-3)ManK1-6(ManK1-
3)Man and dipalmitoylphosphatidylethanolamine. BALB/c
mice were subcutaneously immunized with the liposomes
and induction of CTLs was examined. As shown in Fig. 1,
CTLs that speci¢cally kill target cells pulsed with a synthetic
peptide of the CTL epitope (18I10; RGPGRAFVTI) of the
envelope glycoprotein gp120 of HIV-1 [20] were obtained
from mice subcutaneously immunized with a single dose of
oligomannose-coated liposomes containing the 15-mer peptide
18IIIB. However, none were obtained from mice inoculated
with non-coated liposomes containing the peptide, from oli-
gomannose-coated or non-coated liposomes containing no
peptide or from non-immunized mice. No microabscesses
and no in£ammation was observed at skin sites where the
coated or non-coated liposomes had been injected. CTLs spe-
ci¢c for epitope-pulsed target cells were also obtained even
from mice immunized with oligomannose-coated liposomes
containing 40 Wg of dipalmitoylphosphatidylcholine, 1.2 Wg
of the neoglycolipid, and 0.6 Wg of the peptide (which corre-
sponds to one-¢fth of the liposomes used in the present
study), although the lytic activity of the CTL was slightly
lower than that obtained in the present study (data not
shown). These results indicate that liposomes that are oligo-
mannose-coated with the neoglycolipid perform an adjuvant
activity to induce epitope-speci¢c CTL, but have no toxicity.
In order to examine whether di¡erences in route of immu-
nization would result in di¡erent e¡ects, the same amount of
the oligomannose-coated liposomes containing the peptide
was injected intravenously. The lytic activity of the CTL in-
duced by intravenous injection was somewhat weaker than
that of cells induced by subcutaneous injection (Fig. 1). This
weaker CTL response may be due to degradation of the lipo-
somes in the circulation, resulting in a decrease in the pop-
ulation of CTLs induced by immunization. In any case, the
injection route is important and its signi¢cance should be
further examined, since liposomes must be delivered e¡ectively
to appropriate regions (or cells) before degradation occurs in
vivo.
We then examined the phenotype of the CTLs primed with
the oligomannose-coated liposomes containing the peptide.
E¡ector cells from BALB/c mice immunized with oligoman-
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Fig. 1. Induction of epitope peptide-speci¢c CTL activity by immunization with oligomannose-coated liposomes containing 15-mer peptide
18IIIB. Syngeneic target P815 cells (mastocytoma expressing H-2d) were (a) pulsed with 10-mer peptide 18I10 or (b) untreated. Lytic activity
was measured using spleen cells from BALB/c (H-2d) mice subcutaneously immunized with (1) oligomannose-coated liposomes containing
18IIIB (¢lled circles), (2) non-coated liposomes containing 18IIIB (open circles), (3) oligomannose-coated liposomes containing no peptide (¢lled
triangles), or (4) non-coated liposomes containing no peptide (open triangles); using spleen cells from BALB/c mice intravenously immunized
with the oligomannose-coated liposomes containing 18IIIB (¢lled squares); or using spleen cells from non-immunized BALB/c mice (open
squares).
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nose-coated liposomes containing peptide 18IIIB were pre-
pared as described in Section 2. The cells were then pretreated
with anti-CD8 monoclonal antibody and rabbit complement
or with the complement alone. As shown in Fig. 2, the lytic
activity of the induced CTL was inhibited by pretreatment of
the cells with a mixture of anti-CD8 monoclonal antibody and
rabbit complement, but not with complement alone. This re-
sult indicates that lysis of the target cells was caused by CD8
CTL.
We also examined whether the lytic activity of the induced
CTL was restricted by major histocompatibility complex
(MHC) class I molecules. The lytic activity of the CTL in-
duced in BALB/c (H-2d) mice was examined not only when
using P815 cells expressing H-2d as target cells but also when
using EL4 cells and BW5147 cells expressing H-2b and H-2k,
respectively. As shown in Fig. 3, the induced CTLs were able
to kill peptide 18I10-pulsed P815 cells but unable to kill the
peptide-pulsed EL4 and BW5147 cells. In addition, the CTLs
could lyse not only the P815 cells but also ¢broblast-like cells
(RGB3T3-1) that express H-2d (data not shown). These re-
sults indicate that the lytic activity of the induced CTL was
MHC class I-restricted. From the results so far described, it
was demonstrated that a single immunization with a synthetic
peptide encapsulated into the oligomannose-coated liposomes
can induce epitope-speci¢c, MHC class I-restricted, and CD8
CTL.
The mechanism by which the oligomannose-coated lipo-
somes containing a soluble form of peptide induced the
CTLs is unknown. It is conceivable that a mechanism for
recognizing mannose-rich oligosaccharide structures on the
surface of various infectious agents may have arisen as part
of a defense system utilizing activation of the immune system.
Recent studies have suggested the existence of an interaction
between mannose and mannose receptors on antigen-present-
ing cells, such as macrophages and dendritic cells, which are
involved in cellular immunity [10^15]. It was shown that man-
nose receptors bind strongly to oligosaccharides with mannose
at their non-reducing termini. These ¢ndings are consistent
with our preliminary observations that, among the various
oligosaccharides used to coat liposomes, only the oligoman-
nose type with non-reducing terminal mannose residues had
adjuvant activity that induced the cellular immune response.
Therefore, speci¢c delivery of the epitope peptide to the anti-
gen-presenting cells would have been performed by the oligo-
mannose residues of the neoglycolipid on the surface of the
liposomes. The priming of CTLs in mice immunized with
oligomannose-coated liposomes containing epitope peptide
could be ascribed to the interaction between mannose residues
on the surface of the liposomes and mannose receptors on the
antigen-presenting cells. In addition, oligomannose residues
may perform some other activity, such as stimulation of IL-
12 release, which would result in the activation of T-lympho-
cytes.
It has been reported that mannan-coated liposomes con-
taining a hybrid protein of gag and env of human T lympho-
tropic virus type 1 (HTLV-1) induce MHC class I-restricted
and CD8 CTL speci¢c for HTLV-1-positive cells in rats [21]
and that DNA of HIV-1 incorporated into mannan-coated N-
t-butyl-NP-tetradecyl-3-tetradecylaminopropionamidine or
mannan-coated liposomes elicits HIV-speci¢c CTL activity
[22,23]. This ¢nding (that mannan abundant in mannose res-
idues is important in eliciting CTL response) is consistent with
our ¢nding that oligomannose residues in the neoglycolipids
coated on liposomes are important. From the viewpoint of
practical use, however, these are completely di¡erent. Mannan
is highly immunogenic and toxic [24,25]. Mannan is known to
be lethal when intravenously injected in mice [24] and to in-
duce an antibody response and B-cell mitosis [25]. In addition,
mannan-coated liposomes cause obvious microabscesses at the
skin sites of subcutaneous inoculation [26]. In contrast, oligo-
mannose-coated liposomes were not immunogenic or toxic.
The neoglycolipid used for coating of liposomes in the
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Fig. 3. The CTL response speci¢c for the peptide is restricted to
MHC class I. In order to examine MHC restriction of the CTL re-
sponse induced in BALB/c (H-2d) mice by oligomannose-coated
liposomes containing peptide 18IIIB, P815 cells (H-2d ; squares),
EL4 cells (T-lymphoma expressing H-2b ; circles), and BW5147 cells
(T-lymphoma expressing H-2k ; triangles) were pulsed with peptide
18I10 and then used as target cells. Details of experimental proce-
dures are described in Section 2.
Fig. 2. Oligomannose-coated liposome adjuvant induces CD8
CTL. E¡ector cells from BALB/c mice immunized with oligoman-
nose-coated liposomes containing peptide 18IIIB were prepared as
described in Section 2. The cells were then pretreated with anti-CD8
monoclonal antibody and rabbit complement (open circles) or with
complement alone (open triangles), or left untreated (¢lled circles).
Pretreated or untreated e¡ector cells were mixed with peptide 18I10-
pulsed P815 cells at the indicated ratios.
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present study is composed of innocuous lipid dipalmitoyl-
phosphatidylethanolamine and mannopentaose. Its structure
is included in the high mannose-type oligosaccharides of gly-
coproteins ubiquitously found in bodies of both mice and
humans. Trials to generate antibodies against oligomannose
by repeatedly injecting mice with the neoglycolipid containing
the mannopentaose were unsuccessful. The mice remained
healthy with no sign of adverse e¡ects, suggesting that the
neoglycolipid is not immunogenic or toxic. In the present
study, it was also shown that liposomes that were oligoman-
nose-coated with the neoglycolipid did not cause any damage
to the skin at injection sites. From a practical point of view,
therefore, use of liposomes that are oligomannose-coated with
neoglycolipid o¡ers a novel approach to designing a safe ad-
juvant for inducing e¡ective CTL to control HIV infection
and progression to AIDS, and development of other diseases.
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